FDA approves Johnson & Johnson’s nasal spray for depression

FDA approves first-of-its-kind nasal spray for severe depression
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar psychiatric conditions.
FDA Approves Nasal Spray for Depression
The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to respond to at least two oral antidepressants.
FDA approves Spravato, first monotherapy nasal spray to treat depression
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato was approved to treat a major depressive disorder,
J&J's ketamine-derived nasal spray approved by FDA to treat depression
Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those who had an inadequate response to oral antidepressants.
FDA Approves Spravato Nasal Spray for Treatment-Resistant Depression
WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral antidepressants, according to a news release issued by Johnson & Johnson.
FDA approves standalone use of J&J’s ketamine-derived depression treatment
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the company said on Tuesday.
New Nasal Spray to Treat Depression Gets FDA Approval
The U.S. Food and Drug Administration has approved a nasal spray to treat depression—the first-ever stand-alone medication for patients with severe depression. Johnson & Johnson said patients who use the nasal spray Spravato—which is made from the drug esketamine—may see improvements in depressive symptoms in as little as 24 hours.
FDA allows standalone use of nasal spray antidepressant Spravato
The U.S. Food and Drug Administration has expanded its approval of Spravato, an antidepressant nasal spray. The drug is now cleared for use as a standalone treatment for depression.
Nose spray to treat depression? FDA approves first-of-its-kind medicine
The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday.
Blue Monday isn’t real, but seasonal depression affects millions of people. There are ways to treat it
Blue Monday originated from a publicity stunt, but seasonal affective disorder is a real affliction that affects millions of ...
What's the Connection Between Weight & Depression?
Part of you is concerned — after all, you know depression can be serious — but on the other hand, can’t weight loss be a good ...
mic5h
A Nasal Spray For Depression? FDA Gives Its Approval
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...
Inauguration Day in photos, the allure of coffee shops, how to handle seasonal depression: Catch up on the day’s stories
Inauguration Day in photos, the allure of coffee shops, how to handle seasonal depression: Catch up on the day’s stories ...
Drawing a line from the gut microbiome to inflammation and depression
It's become increasingly clear that the gut microbiome can affect human health, including mental health. Which bacterial ...
Medscape5d
Can Walking More Steps Per Day Help Keep Depression Away?
Higher daily step counts were linked to fewer depressive symptoms and a lower risk for depression in a new meta-analysis.
New Scientist6d
What can we learn from a debunked theory of depression?
Rebutting the serotonin theory of depression exposed an important gap in our knowledge. But Joanna Moncrieff's new book ...
Why a common asthma drug will now carry extra safety warnings about depression
The TGA has issued a requirement for new warnings to be provided with the drug montelukast, commonly used to treat asthma and ...